Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.
News|Articles|February 26, 2025
- Vol. 26/No. 4
- Volume 26
- Issue 4
Tips for Tomorrow: What 4 Experts Wish They Knew Earlier About ADCs
Author(s)Megan Hollasch
Fact checked by: Caroline Seymour
Clinicians with years of ADC therapy experience provide insights on the drug class and what is most important to keep in mind when treating patients.
Advertisement
Advertisement
Although antibody-drug conjugates (ADCs) have been approved in select tumor types for years now, the 2024 tumor-agnostic approval of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for select patients has provided the first ever ADC option in many cancers.1
Related to this article
The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
Advances in endocrine therapy, immunotherapy, and ADCs frame unresolved breast cancer treatment questions ahead of BTG 2026.
Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.
Are we ready to “take that fork in the road” and move palliative/supportive care into routine cancer care?
Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
Keith Flaherty, MD, FAACR, discusses the 2026 AACR Cancer Progress Report and how the oncology field can build on the report’s findings.
Advertisement
Advertisement